



Orelabrutinib – Potential Best-in-Class BTK Inhibitor

- **Orelabrutinib demonstrates compelling efficacy**
 - In 80 patients with R/R CLL, at median follow-up of 32.3 months, ORR was 93.8%, CR was 24%, CRi was 2%. mDoR NR
 - In 99 patients with R/R MCL, at median follow-up of 23.8 months, ORR was 88%, CR was 37%, mDoR was 26-mo
- **Orelabrutinib shows class leading safety and tolerability in patients with various b-cell malignancies**
 - No case of ≥ 3 Grade 3 A-fib, rare case of major bleeding/severe hypertension/diarrhea
 - Most common AE are Grade 1-2, occurring during the early course of treatment
 - 5% of patients discontinued treatment due to AE, 2% were treatment related
- **Orelabrutinib has demonstrated similar efficacy and safety profile in US patients**
- **Orelabrutinib has been granted Breakthrough Therapy Designation for r/r MCL indication by the FDA**
- **We are recruiting BTKi treatment naïve r/r MCL patients for our US registration study**

STAND STRONG TO DEFEND PATIENTS

DISCOVER A DIFFERENT APPROACH TO TREATMENT



Scan the QR code or visit
TAVALISSEhcp.com to learn about
a different approach to treatment.

Tavalisse
(fostamatinib disodium
hexahydrate) tablets

© 2022 Rigol Pharmaceuticals, Inc. All rights reserved. TAVA JTP-22158 0822
TAVALISSE is a registered trademark of Rigol Pharmaceuticals, Inc.



The image depicted contains models and is being used for illustrative purposes only. Janssen Research & Development, LLC. © JRD, LLC 2022

A powerful way to fight cancer lives inside your body.

To fight cancer, we are developing immunotherapies that
work with the body's natural defenses. Helping us get
closer to a future where disease is a thing of the past.
Learn more at www.janssen.com.

janssen  Oncology
PHARMACEUTICAL COMPANIES OF 